An observational study in Endogenous Cushing's Syndrome, sponsored by RECORDATI GROUP. Active, not recruiting at 43 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by RECORDATI GROUP · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Cushing Syndrome with a site in United States — 14 open to participants now, 17 under way, none of them phase 3. Cushing Syndrome · United States.
Among the 58 studies in Cushing Syndrome with a site in United States, this one is the 12th largest by enrollment of the 23 observational ones that give a count, is one of 3 that started in 2022, is one of 24 observational ones, reaches primary completion later than 3 of the 16 other live ones, and was the 45th registered.
123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.
Browse Cushing Syndrome studies →14 of the 58 studies in Cushing Syndrome with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
RECORDATI GROUP · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Sparrow Pharmaceuticals · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 20 · Phase 3 8 · Phase 4 4
First in 1982; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 206 is above the median of 121 across 63 observational studies indexed under Cushing Syndrome.
Median enrollment 35 across the 34 interventional studies, 206 across the 23 observational. Of the 38 that completed or were terminated, 15 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 58 have an industry lead sponsor. The 10 most frequent:
RECORDATI GROUP is the lead sponsor of 21 studies on the registry; 3 are open to participants now.
RECORDATI GROUP has 5 studies filed under Cushing Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Cushing Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03364803Memorial Sloan Kettering Cancer CenterCollecting Information About Treatment Results for Patients With Cushing's Syndrome | 2026-11-28 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07104812Mayo ClinicImpact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) | 2027-01 |
| NCT05382156RECORDATI GROUPNon-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome | 2027-06 |
| NCT03708900RECORDATI GROUPPharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome | 2027-07-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 58 studies in Cushing Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome
This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome. This study is observational in nature and does not impose a therapy protocol, diagnostic/therapeutic interventions or a visit schedule.
Patients with endogenous Cushing's Syndrome who are treated with osilodrostat alone or in combination with other therapies will be considered eligible for study enrolment. Each patient enrolled in the study will be followed up for 3 years from study entry. Patients who discontinue prior to the end of the 3-year period will be followed-up for 3 months after discontinuation of osilodrostat and will be included in the analysis.
The total number of patients enrolled in this study will be approximately 201. Assuming a recruitment period of 3 years, the total study duration from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) will be 6 years. The maximum duration for the individual patient is 3 years.
The patient population will consist of adult male and female patients with endogenous Cushing's Syndrome. Eligible patients for the study must be treated with osilodrostat. Investigators need to ensure that patients enrolled in this study meet the study inclusion and exclusion criteria listed in the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Osilodrostat - tablets of 1mg, 5mg, 10mg - based on patients needs - up to 3 years
Drug: Osilodrostat
oral administration of Osilodrostat tablets at different doses according to patient's need
Also known as: Isturisa
Incidence of osilodrostat-related adverse events and serious adverse events
Number of participants with Adverse Events and Serious Adverse Events
Time frame: 3 years of treatment with osilodrostat
Short and long-term efficacy of osilodrostat
Complete response rate: proportion of enrolled patients with mean Urinary Free Cortisol (mUFC) ≤ ULN
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months in the first year and every 6 months thereafter through study completion up to three years
Short and long-term efficacy of osilodrostat
Partial response rate: proportion of enrolled patients with ≥ 50% reduction from baseline in mean urinary free cortisol (mUFC), (but mUFC \> ULN)
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months in the first year and every 6 months thereafter through study completion up to three years
Short and long-term efficacy of osilodrostat
Overall response rate: proportion of enrolled patients with mean urinary free cortisol (mUFC) ≤ ULN or at least 50% reduction from baseline
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months in the first year and every 6 months thereafter through study completion up to three years
Changes in pituitary tumour size
Actual and percentage change from baseline in pituitary tumour size
Time frame: at baseline before treatment start, after 6 months of treatment, then every 12 months through study completion up to three years
Incidence of Adverse Events (Safety and Tolerability)
Incidence of adverse events and laboratory abnormalities using the National Cancer Institute-Common Toxicology Criteria (NCI-CTC) grading scale (version 5.0).
Time frame: 3 years of treatment with osilodrostat
Change of mean urinary free cortisol (mUFC)
Actual and percentage change from baseline in mean urinary free cortisol (mUFC)
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years
Change of Serum Cortisol
Actual and percentage change from baseline in Serum Cortisol
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years
Change of Late Salivary Cortisol
Actual and percentage change from baseline in Late Salivary Cortisol
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years
Change of adrenocorticotropic hormone (ACTH)
Actual and percentage change from baseline in adrenocorticotropic hormone (ACTH)
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years
Normalization of Serum Cortisol
Proportion of patients achieving normalisation of Serum Cortisol
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years
Normalization of Late Salivary Cortisol
Proportion of patients achieving normalisation of Late Salivary Cortisol
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years
Normalization of adrenocorticotropic hormone (ACTH)
Proportion of patients achieving normalisation of adrenocorticotropic hormone (ACTH)
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years
Change in Fasting Glucose
Actual and percentage change from baseline in fasting glucose
Time frame: at baseline before treatment start, then every 3 months through study completion up to three years
Change in HbA1c
Actual and percentage change from baseline in HbA1c
Time frame: at baseline before treatment start, then every 3 months through study completion up to three years
Change in Fasting Lipid Profile
Actual and percentage change from baseline in Fasting Lipid Profile
Time frame: at baseline before treatment start, then every 3 months through study completion up to three years
Change in Serum Insulin
Actual and percentage change from baseline in Serum Insulin
Time frame: at baseline before treatment start, then every 3 months through study completion up to three years
Change in Blood Pressure
Actual and percentage change from baseline in Blood Pressure
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years
Change in Body Weight
Actual and percentage change from baseline in Body Weight
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years
Change in Body Mass Index (BMI)
Actual and percentage change from baseline in Body Mass Index (BMI)
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years
Change in Waist Circumference
Actual and percentage change from baseline in Waist Circumference
Time frame: at baseline before treatment start, after 1 month of treatment, then every 3 months through study completion up to three years
Change in Facial Rubor
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Facial Rubor
Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years
Change in Hirsutism
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Hirsutism
Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years
Change in Striae
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Striae
Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years
Change in Supraclavicular fat pad
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Supraclavicular fat pad
Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years
Change in Dorsal fat pad
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Dorsal fat pad
Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years
Change in Proximal muscle wasting (atrophy)
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Proximal muscle wasting (atrophy)
Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years
Change in Central (abdominal) obesity
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Central (abdominal) obesity
Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years
Change in Ecchymoses (bruises)
Change from baseline in incidence and grade of severity at physical examination of the Cushing's syndrome clinical feature Ecchymoses (bruises)
Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years
Changes in Patient-Reported Outcome (PRO) questionnaire Cushing Quality of Life (QoL)
Actual and percentage change from baseline in score of PRO questionnaire CushingQoL. The minimum and maximum values are 12 and 60 respectively, where higher score means a better outcome
Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years
Changes in Patient-Reported Outcome (PRO) questionnaire Euro Quality of Life (EQ) - 5 Dimensions (5D) - 5 Levels (5L)
Actual and percentage change from baseline in score of PRO questionnaire EQ-5D-5L. The minimum and maximum values for the questions are 11111 and 55555 respectively, where higher score is a worst outcome. For the visual analogue scale minimum and maximum values are 0 and 100 respectively, where higher score means a better outcome
Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years
Changes in Patient-Reported Outcome (PRO) questionnaire Beck Depression Inventory II (BDI-II)
Actual and percentage change from baseline in score of PRO questionnaire BDI-II. The minimum and maximum values are 1 and 63 respectively, where higher score means a worse outcome
Time frame: at baseline before treatment start, after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years
Changes in Patient-Reported Outcome (PRO) questionnaire Patient Global Impression of Change (PGIC)
Actual and percentage change in score of PRO questionnaire PGIC. The minimum and maximum values of the question are 1 and 7 respectively, where higher score means a better outcome. For the visual analogue scale minimum and maximum values are 0 and 10 respectively, where higher score means a worse outcome
Time frame: after 3 months of treatment, after 6 months of treatment, then every 6 months through study completion up to three years
Plan to share: Yes
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for Jun 2027, 60 months after the start.
Of 31 observational studies under Cushing Syndrome, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 85. This study's planned 60 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.